IGF-1 LR3 1mg/vial 1 Vial by Master Pharma

Usage

1. Retrieve the lyophilised vial from −20 °C storage and allow it to reach room temperature for 10–15 minutes before handling.
2. Reconstitute using bacteriostatic water; inject diluent slowly down the inner vial wall to avoid mechanical shear degradation of the peptide.
3. Gently swirl — never vortex — until the lyophilised cake is fully dissolved; the solution should be clear and colourless.
4. For systemic LR3 protocols, draw the calculated dose into a 28–31 gauge insulin syringe and administer subcutaneously into the abdomen or thigh.
5. Time the injection according to your research protocol: once-daily morning (fasted) or immediately post-workout are the most common reference schedules for IGF-1 LR3.
6. Cap and refrigerate the reconstituted vial at 2–8 °C immediately after use; log the reconstitution date and discard any remaining solution after 28 days.

Warnings

Frequently asked questions

When should a researcher use IGF-1 LR3 instead of IGF-1 DES for muscle growth protocols?

IGF-1 LR3 is the appropriate choice when the research goal is systemic, whole-body anabolic signalling across multiple muscle groups over an extended period. IGF-1 DES, by contrast, is selected when the protocol targets localised, site-specific muscle hypertrophy at a single injection site — typically administered immediately pre-workout directly into the target muscle. LR3's 20–30-hour half-life supports once-daily dosing; DES requires intra-workout timing for site-concentrated effect.

Why is IGF-1 DES injected pre-workout directly into the target muscle rather than subcutaneously?

IGF-1 DES lacks the first three N-terminal amino acids present in LR3, which eliminates most IGFBP-binding capacity but also sharply reduces systemic circulation time to under 30 minutes. Intramuscular pre-workout injection places the peptide directly at the target receptor site before blood flow from exercise further concentrates local delivery. Subcutaneous administration results in too-rapid systemic dilution and loss of the localisation effect central to DES protocols.

How short is the plasma half-life of IGF-1 DES compared to IGF-1 LR3?

IGF-1 DES carries an estimated plasma half-life of under 30 minutes in vitro, attributed to its absent N-terminal tripeptide and consequent inability to bind circulating IGFBPs. IGF-1 LR3 achieves approximately 20–30 hours of active systemic circulation under the same pharmacokinetic research conditions. This roughly 40-to-60-fold difference in half-life is the primary factor determining whether a protocol targets local or systemic anabolic pathways.

How does the 1mg/vial format of Master Pharma IGF-1 LR3 affect dosing flexibility for research?

The 1 mg/vial concentration is the entry-level format in this product group and is well-suited to short-cycle or introductory research designs. At 50 mcg per injection — a common research reference dose — a single vial yields 20 individual doses. Researchers requiring longer multi-week protocols at higher per-dose volumes may need multiple vials; this format minimises upfront commitment while maintaining full analytical traceability per lot.

What storage conditions are required after reconstituting Master Pharma IGF-1 LR3 in a 1mg/vial?

Once reconstituted, IGF-1 LR3 should be stored at 2–8 °C in a refrigerator and kept away from light exposure. Reconstituted solutions are stable for up to 28 days under these conditions when bacteriostatic water is used as the diluent. The lyophilised vial prior to reconstitution should be stored at or below −20 °C for long-term preservation. Use a 28–31 gauge insulin syringe for precise low-volume withdrawals to minimise peptide degradation from repeated needle entry. (2) angle_used

Manufacturer

Customer reviews and independent ratings for Master Pharma's peptide line point consistently to two performance indicators: lot-to-lot consistency and reconstitution behaviour. Across verified purchaser accounts for IGF-1 LR3, users describe vial cakes that dissolve cleanly and solutions that remain clear throughout the stated 28-day refrigerated window — an outcome that reflects upstream lyophilisation process control rather than chance. Master Pharma's internal quality review process incorporates post-market feedback as a secondary signal alongside formal analytical data; where recurring field reports flag reconstitution anomalies or particulate observations, batch documentation is re-examined. This feedback loop between customer experience and internal QC records is a defining operational characteristic that distinguishes Master Pharma from manufacturers who treat analytical release as the sole quality endpoint.